Completed PHASE2 INTERVENTIONAL 1-arm NCT00948727

Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation (CALCICLO)

Reduction of Acute and Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem-cell Transplantation by Adapting Cyclosporine Doses According to Calcineurin Activity : a Proof-of-concept Trial

Sponsor: Agence de La Biomédecine

Conditions Graft Versus Host Disease Hematopoietic Stem Cell Transplantation

Interventions Cyclosporine (CsA) Dose adaptation according to CN activity monitoring

Updated 5 times since 2017 Last updated: Sep 30, 2009 Started: Jan 31, 2004 Primary completion: Sep 30, 2006 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Graft Versus Host Disease and Hematopoietic Stem Cell Transplantation, this trial is completed. The trial is conducted by Agence de La Biomédecine and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agence de La Biomédecine
Assistance Publique - Hôpitaux de Paris

Data source: Assistance Publique - Hôpitaux de Paris

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Créteil, France